APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dolutegravir & Rilpivirine Combination Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Dolutegravir & Rilpivirine Combination Drug Industry Growth and Trends Forecast to 2032

23 December 202572 pages

Choose your research edition.

Industry ResearchDolutegravir & Rilpivirine Combination Drug Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Dolutegravir & Rilpivirine Combination Drug Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Dolutegravir & Rilpivirine Combination Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dolutegravir & Rilpivirine Combination Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Dolutegravir & Rilpivirine Combination Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Dolutegravir & Rilpivirine Combination Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Dolutegravir & Rilpivirine Combination Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Dolutegravir & Rilpivirine Combination Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dolutegravir & Rilpivirine Combination Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dolutegravir & Rilpivirine Combination Drug include ViiV Healthcare and JNJ among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Dolutegravir & Rilpivirine Combination Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Dolutegravir & Rilpivirine Combination Drug market size, estimates, and forecasts are presented in terms of sales volume (k pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Dolutegravir & Rilpivirine Combination Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Dolutegravir & Rilpivirine Combination Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Dolutegravir & Rilpivirine Combination Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Dolutegravir & Rilpivirine Combination Drug Market by Company

ViiV Healthcare

JNJ

Dolutegravir & Rilpivirine Combination Drug Segment by Type

Self-production API

Outsourcing of API

Dolutegravir & Rilpivirine Combination Drug Segment by Application

Clinic

Hospital

Drug Center

Others

Dolutegravir & Rilpivirine Combination Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dolutegravir & Rilpivirine Combination Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dolutegravir & Rilpivirine Combination Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dolutegravir & Rilpivirine Combination Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dolutegravir & Rilpivirine Combination Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Dolutegravir & Rilpivirine Combination Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Self-production API Table 2. Major Company of Outsourcing of API Table 3. Global Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 5. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type (2021-2026) Table 6. Global Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 7. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type (2021-2026) Table 8. Global Dolutegravir & Rilpivirine Combination Drug Price by Type (2021-2026) & (US$/pcs) Table 9. Global Dolutegravir & Rilpivirine Combination Drug Sales by Type (2027-2032) & (k pcs) Table 10. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type (2027-2032) Table 11. Global Dolutegravir & Rilpivirine Combination Drug Sales by Type (2027-2032) & (US$ Million) Table 12. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type (2027-2032) Table 13. Global Dolutegravir & Rilpivirine Combination Drug Price by Type (2027-2032) & (US$/pcs) Table 14. North America Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 15. North America Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 17. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 19. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 21. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (k pcs) Table 23. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Dolutegravir & Rilpivirine Combination Drug Industry Trends Table 25. Dolutegravir & Rilpivirine Combination Drug Industry Drivers Table 26. Dolutegravir & Rilpivirine Combination Drug Industry Opportunities and Challenges Table 27. Dolutegravir & Rilpivirine Combination Drug Industry Restraints Table 28. Global Dolutegravir & Rilpivirine Combination Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Dolutegravir & Rilpivirine Combination Drug Revenue Market Share by Company (2021-2026) Table 30. Global Dolutegravir & Rilpivirine Combination Drug Sales by Company (2021-2026) & (k pcs) Table 31. Global Dolutegravir & Rilpivirine Combination Drug Sales Share by Company (2021-2026) Table 32. Global Dolutegravir & Rilpivirine Combination Drug Market Price by Company (2021-2026) & (US$/pcs) Table 33. Global Dolutegravir & Rilpivirine Combination Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Dolutegravir & Rilpivirine Combination Drug Major Company Production Sites and Headquarters Table 35. Global Dolutegravir & Rilpivirine Combination Drug Company, Product Type & Application Table 36. Global Dolutegravir & Rilpivirine Combination Drug Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Dolutegravir & Rilpivirine Combination Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Dolutegravir & Rilpivirine Combination Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Dolutegravir & Rilpivirine Combination Drug Sales by Region (2021-2026) & (k pcs) Table 41. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Region (2021-2026) Table 42. Global Dolutegravir & Rilpivirine Combination Drug Sales by Region (2021-2026) & (US$ Million) Table 43. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Region (2021-2026) Table 44. Global Dolutegravir & Rilpivirine Combination Drug Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 45. Global Dolutegravir & Rilpivirine Combination Drug Sales by Region (2027-2032) & (k pcs) Table 46. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Region (2027-2032) Table 47. Global Dolutegravir & Rilpivirine Combination Drug Sales by Region (2027-2032) & (US$ Million) Table 48. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Region (2027-2032) Table 49. Global Dolutegravir & Rilpivirine Combination Drug Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2027-2032) Table 50. Global Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 52. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application (2021-2026) Table 53. Global Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 54. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application (2021-2026) Table 55. Global Dolutegravir & Rilpivirine Combination Drug Price by Application (2021-2026) & (US$/pcs) Table 56. Global Dolutegravir & Rilpivirine Combination Drug Sales by Application (2027-2032) & (k pcs) Table 57. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application (2027-2032) Table 58. Global Dolutegravir & Rilpivirine Combination Drug Sales by Application (2027-2032) & (US$ Million) Table 59. Global Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application (2027-2032) Table 60. Global Dolutegravir & Rilpivirine Combination Drug Price by Application (2027-2032) & (US$/pcs) Table 61. North America Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 62. North America Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 64. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 66. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 68. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (k pcs) Table 70. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Application (2021-2026) & (US$ Million) Table 71. ViiV Healthcare Company Information Table 72. ViiV Healthcare Business Overview Table 73. ViiV Healthcare Dolutegravir & Rilpivirine Combination Drug Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. ViiV Healthcare Dolutegravir & Rilpivirine Combination Drug Product Portfolio Table 75. ViiV Healthcare Recent Development Table 76. JNJ Company Information Table 77. JNJ Business Overview Table 78. JNJ Dolutegravir & Rilpivirine Combination Drug Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. JNJ Dolutegravir & Rilpivirine Combination Drug Product Portfolio Table 80. JNJ Recent Development Table 81. North America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 82. North America Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026) & (k pcs) Table 83. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share by Country (2021-2026) Table 84. North America Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032) & (k pcs) Table 85. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share Forecast by Country (2027-2032) Table 86. North America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 87. North America Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026) & (US$ Million) Table 88. North America Dolutegravir & Rilpivirine Combination Drug Market Share by Country (2021-2026) Table 89. North America Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 90. North America Dolutegravir & Rilpivirine Combination Drug Market Share Forecast by Country (2027-2032) Table 91. Europe Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 92. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026) & (k pcs) Table 93. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share by Country (2021-2026) Table 94. Europe Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032) & (k pcs) Table 95. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share Forecast by Country (2027-2032) Table 96. Europe Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 97. Europe Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026) & (US$ Million) Table 98. Europe Dolutegravir & Rilpivirine Combination Drug Market Share by Country (2021-2026) Table 99. Europe Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 100. Europe Dolutegravir & Rilpivirine Combination Drug Market Share Forecast by Country (2027-2032) Table 101. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 102. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026) & (k pcs) Table 103. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share by Country (2021-2026) Table 104. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032) & (k pcs) Table 105. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share Forecast by Country (2027-2032) Table 106. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026) & (US$ Million) Table 108. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Share by Country (2021-2026) Table 109. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Share Forecast by Country (2027-2032) Table 111. Latin America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 112. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026) & (k pcs) Table 113. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share by Country (2021-2026) Table 114. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032) & (k pcs) Table 115. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share Forecast by Country (2027-2032) Table 116. Latin America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Latin America Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026) & (US$ Million) Table 118. Latin America Dolutegravir & Rilpivirine Combination Drug Market Share by Country (2021-2026) Table 119. Latin America Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Latin America Dolutegravir & Rilpivirine Combination Drug Market Share Forecast by Country (2027-2032) Table 121. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 122. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026) & (k pcs) Table 123. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share by Country (2021-2026) Table 124. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032) & (k pcs) Table 125. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share Forecast by Country (2027-2032) Table 126. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026) & (US$ Million) Table 128. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Share by Country (2021-2026) Table 129. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Share Forecast by Country (2027-2032) Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Dolutegravir & Rilpivirine Combination Drug Distributors List Table 134. Dolutegravir & Rilpivirine Combination Drug Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Dolutegravir & Rilpivirine Combination Drug Image Figure 2. Global Dolutegravir & Rilpivirine Combination Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dolutegravir & Rilpivirine Combination Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dolutegravir & Rilpivirine Combination Drug Sales (2021-2032) & (k pcs) Figure 5. Self-production API Image Figure 6. Global Self-production API Sales YoY Growth (2021-2032) & (k pcs) Figure 7. Outsourcing of API Image Figure 8. Global Outsourcing of API Sales YoY Growth (2021-2032) & (k pcs) Figure 9. Global Dolutegravir & Rilpivirine Combination Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Dolutegravir & Rilpivirine Combination Drug Market Share by Type 2025 VS 2032 Figure 11. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type in 2025 Figure 12. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type in 2025 Figure 13. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type in 2025 Figure 14. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type in 2025 Figure 17. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Dolutegravir & Rilpivirine Combination Drug Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Clinic Image Figure 24. Global Clinic Sales YoY Growth (2021-2032) & (k pcs) Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (k pcs) Figure 27. Drug Center Image Figure 28. Global Drug Center Sales YoY Growth (2021-2032) & (k pcs) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (k pcs) Figure 31. Global Dolutegravir & Rilpivirine Combination Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Dolutegravir & Rilpivirine Combination Drug Market Share by Application 2025 VS 2032 Figure 33. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application in 2025 Figure 34. North America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application in 2025 Figure 35. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application in 2025 Figure 36. Europe Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application in 2025 Figure 39. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Market Share in Value by Application in 2025 Figure 43. North America Dolutegravir & Rilpivirine Combination Drug Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 44. North America Dolutegravir & Rilpivirine Combination Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Dolutegravir & Rilpivirine Combination Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Dolutegravir & Rilpivirine Combination Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Dolutegravir & Rilpivirine Combination Drug Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 48. Europe Dolutegravir & Rilpivirine Combination Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Dolutegravir & Rilpivirine Combination Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Dolutegravir & Rilpivirine Combination Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 52. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Dolutegravir & Rilpivirine Combination Drug Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 56. Latin America Dolutegravir & Rilpivirine Combination Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Dolutegravir & Rilpivirine Combination Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Dolutegravir & Rilpivirine Combination Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 60. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Dolutegravir & Rilpivirine Combination Drug Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Dolutegravir & Rilpivirine Combination Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Self-production API
  • Outsourcing of API
Applications
  • Clinic
  • Hospital
  • Drug Center
  • Others
Companies covered
  • ViiV Healthcare
  • JNJ

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dolutegravir & Rilpivirine Combination Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Dolutegravir & Rilpivirine Combination Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Dolutegravir & Rilpivirine Combination Drug Market by Type
  6. 1.3.1 Self-production API
  7. 1.3.2 Outsourcing of API
  8. 1.4 Global Dolutegravir & Rilpivirine Combination Drug Market Size by Type
  9. 1.4.1 Global Dolutegravir & Rilpivirine Combination Drug Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Dolutegravir & Rilpivirine Combination Drug Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Dolutegravir & Rilpivirine Combination Drug Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Dolutegravir & Rilpivirine Combination Drug Industry Trends
  2. 2.2 Dolutegravir & Rilpivirine Combination Drug Industry Drivers
  3. 2.3 Dolutegravir & Rilpivirine Combination Drug Industry Opportunities and Challenges
  4. 2.4 Dolutegravir & Rilpivirine Combination Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Dolutegravir & Rilpivirine Combination Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Dolutegravir & Rilpivirine Combination Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Dolutegravir & Rilpivirine Combination Drug Price (2021-2026)
  4. 3.4 Global Dolutegravir & Rilpivirine Combination Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dolutegravir & Rilpivirine Combination Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Dolutegravir & Rilpivirine Combination Drug Company, Product Type & Application
  7. 3.7 Global Dolutegravir & Rilpivirine Combination Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dolutegravir & Rilpivirine Combination Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dolutegravir & Rilpivirine Combination Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dolutegravir & Rilpivirine Combination Drug Tier 1, Tier 2, and Tier 3
4 Dolutegravir & Rilpivirine Combination Drug Regional Status and Outlook
  1. 4.1 Global Dolutegravir & Rilpivirine Combination Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Dolutegravir & Rilpivirine Combination Drug Historic Market Size by Region
  3. 4.2.1 Global Dolutegravir & Rilpivirine Combination Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Dolutegravir & Rilpivirine Combination Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Dolutegravir & Rilpivirine Combination Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Dolutegravir & Rilpivirine Combination Drug Forecasted Market Size by Region
  7. 4.3.1 Global Dolutegravir & Rilpivirine Combination Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Dolutegravir & Rilpivirine Combination Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Dolutegravir & Rilpivirine Combination Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Dolutegravir & Rilpivirine Combination Drug by Application
  1. 5.1 Dolutegravir & Rilpivirine Combination Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Drug Center
  5. 5.1.4 Others
  6. 5.2 Global Dolutegravir & Rilpivirine Combination Drug Market Size by Application
  7. 5.2.1 Global Dolutegravir & Rilpivirine Combination Drug Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Dolutegravir & Rilpivirine Combination Drug Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Dolutegravir & Rilpivirine Combination Drug Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 ViiV Healthcare
  2. 6.1.1 ViiV Healthcare Company Information
  3. 6.1.2 ViiV Healthcare Business Overview
  4. 6.1.3 ViiV Healthcare Dolutegravir & Rilpivirine Combination Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 ViiV Healthcare Dolutegravir & Rilpivirine Combination Drug Product Portfolio
  6. 6.1.5 ViiV Healthcare Recent Developments
  7. 6.2 JNJ
  8. 6.2.1 JNJ Company Information
  9. 6.2.2 JNJ Business Overview
  10. 6.2.3 JNJ Dolutegravir & Rilpivirine Combination Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 JNJ Dolutegravir & Rilpivirine Combination Drug Product Portfolio
  12. 6.2.5 JNJ Recent Developments
7 North America by Country
  1. 7.1 North America Dolutegravir & Rilpivirine Combination Drug Sales by Country
  2. 7.1.1 North America Dolutegravir & Rilpivirine Combination Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Dolutegravir & Rilpivirine Combination Drug Market Size by Country
  6. 7.2.1 North America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Dolutegravir & Rilpivirine Combination Drug Sales by Country
  2. 8.1.1 Europe Dolutegravir & Rilpivirine Combination Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Dolutegravir & Rilpivirine Combination Drug Market Size by Country
  6. 8.2.1 Europe Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Country
  2. 9.1.1 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Dolutegravir & Rilpivirine Combination Drug Sales by Country
  2. 10.1.1 South America Dolutegravir & Rilpivirine Combination Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Dolutegravir & Rilpivirine Combination Drug Market Size by Country
  6. 10.2.1 South America Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Country
  2. 11.1.1 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Dolutegravir & Rilpivirine Combination Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Dolutegravir & Rilpivirine Combination Drug Value Chain Analysis
  2. 12.1.1 Dolutegravir & Rilpivirine Combination Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Dolutegravir & Rilpivirine Combination Drug Production Mode & Process
  7. 12.2 Dolutegravir & Rilpivirine Combination Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Dolutegravir & Rilpivirine Combination Drug Distributors
  10. 12.2.3 Dolutegravir & Rilpivirine Combination Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst